Teladoc (TDOC) Announces Second Consecutive Win in Patent Dispute
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Teladoc, Inc. (NYSE: TDOC), the nation’s first and largest telehealth provider, today announced the U.S. Patent and Trademark Office (USPTO) has invalidated the major elements of a telemedicine patent held by American Well Corporation on the basis that they were not patentable because American Well did not invent them. The USPTO took this action at the request of Teladoc. At issue before the USPTO were the same elements of the American Well patent that a Massachusetts federal court declared invalid earlier this year on a separate basis.
“For more than a year, we have challenged American Well’s patent portfolio as invalid, advocating on behalf of the industry so innovation and increased access to health care can continue to thrive,” said Adam Vandervoort, Teladoc chief legal officer. “Teladoc is extremely pleased by the decisions of both the U.S. Patent and Trademark Office and the Massachusetts federal court.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
- Atmos Energy (ATO) Announces Departure of CFO Bret Eckert
- DryShips (DRYS) Acquires Its First VLGC With 5 Year Time Charter Attached to Oil Major
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!